How Immunotherapy for Cancer Helps the Immune System Target Cancer Cells

Cancer cells can avoid immune surveillance by hiding abnormal markers, reducing antigen presentation, or creating a tumor environment that suppresses T cells. You will learn how each major immunotherapy approach restores recognition or supplies cancer-targeting immune cells, how doctors select patients, and what treatment and monitoring involve.

Key takeaways

  • Cancer cells can hide by weakening immune signals or disguising abnormal antigens.
  • Checkpoint inhibitors remove brakes that stop T cells from attacking cancer.
  • Biomarker testing helps identify cancers more likely to respond to immunotherapy.
  • Report new symptoms promptly because immune reactions can affect healthy organs.

How the Immune System Recognizes Cancer—and How Tumors Hide

Your immune system finds abnormal cells through immune surveillance. Healthy cells display protein fragments on their surfaces through antigen presentation, giving T cells a sample of what is inside. If a cell displays an unusual antigen, such as a fragment created by a cancer-causing mutation, T cells can recognize it and destroy the cell.

Cancer escapes detection by changing the signals that immune cells rely on:

  • It reduces antigen presentation, so T cells receive little or no visible evidence of the abnormal cell.
  • It alters or loses the antigens that T cells recognize, creating a moving target.
  • It builds a tumor microenvironment containing signals and cells that suppress immune activity.
  • It sends inhibitory signals that restrain T cells before they can sustain an attack.

Tumors with defective mismatch repair or high microsatellite instability accumulate many DNA errors. Those errors can produce more abnormal proteins, called neoantigens, which make the cancer easier for T cells to spot.

A high tumor mutational burden can point in the same direction, but mutation count alone does not prove that T cells can reach, recognize, or kill the tumor.

Immunotherapy therefore does not simply “boost” immunity. It works only when cancer cells display a target, immune cells can reach the tumor, and the relevant immune pathway can be reactivated. A tumor can meet one condition and still evade treatment.

The Main Ways Immunotherapy Restarts or Directs an Immune Attack

Immunotherapy does not simply raise all immune activity. Each approach removes a brake, marks cancer for attack, teaches recognition, equips T cells, or supplies signals that strengthen an existing response.

- Immune checkpoint inhibitors release inhibitory signals on T cells. PD-1 or PD-L1 blockade can restore T-cell activity inside a tumor, while CTLA-4 blockade acts earlier during T-cell activation. These medicines do not directly poison cancer cells, so they work only when T cells can recognize and reach them.

- Monoclonal antibodies attach to a specific protein on cancer cells. The coating can block a growth signal, flag the cell for immune destruction, or deliver a drug or radiation payload directly to it.

- Cancer vaccines present tumor-associated antigens to the immune system, helping immune cells identify cancer more precisely. They strengthen recognition rather than kill every cancer cell immediately.

- CAR-T therapy removes T cells, equips them in a laboratory with a receptor for a defined cancer target, and returns them to the bloodstream. It has its strongest established role in several blood cancers; solid tumors are harder because targets can occur on healthy tissue.

- Cytokines such as interleukins and interferons act as immune signals. They can expand or activate immune cells, but broad stimulation also raises the risk of serious inflammation.

Which Patients and Cancers May Benefit from Immunotherapy?

A cancer immunotherapy eligibility decision starts with the cancer’s type and stage. Immunotherapy has established roles in cancers such as melanoma, lung, kidney, bladder, and several blood cancers, but the useful drug and treatment timing differ between early, locally advanced, and metastatic disease.

A biopsy and pathology report confirm the cancer type, grade, spread, and features that guide treatment.

FactorWhat clinicians examineHow it changes the decision
Cancer and stageTumour site, spread, and whether treatment is before or after surgeryImmunotherapy may shrink a tumour before surgery, reduce recurrence risk after surgery, or control advanced disease
BiomarkersPD-L1 immunohistochemistry, mismatch-repair or microsatellite-instability status, and sometimes tumour mutational burdenA positive result can support a checkpoint inhibitor; a negative result does not always rule it out
Previous treatmentSurgery, chemotherapy, radiation, targeted therapy, and earlier immunotherapyResults, resistance, treatment-free interval, and remaining options influence the next regimen

Overall health can alter the balance. Active autoimmune disease, an organ transplant, immunosuppressive medicines, uncontrolled infection, poor organ function, or planned surgery may make immune checkpoint treatment unsafe or require specialist coordination.

Dr.Parag Ingle - Surgical Oncologist can help interpret the biopsy, pathology report, biomarker results, and surgical plan together rather than treating one test as the final answer.

Even with a suitable biomarker, cancer can evade immune attack by reducing antigen presentation or suppressing immune cells around the tumour. Eligibility therefore identifies a reasonable treatment option, not a guaranteed response.

Related service

Immunotherapy for cancer

Immunotherapy for cancer

Revolutionizing cancer treatment, our Immunotherapy services harness the power of the body's own immune system to combat cancer cells effectively.

View service →

What an Immunotherapy Treatment Visit and Safety Monitoring Involve

An intravenous infusion visit usually includes a symptom review, vital signs, blood tests, and a check of liver, kidney, thyroid, and blood-cell function. The drug is delivered over a set period, followed by observation for allergic reactions or sudden breathing and blood-pressure changes.

Treatment cycles may repeat every few weeks, depending on the drug and cancer.

Treatment typeWhat the visit involvesMain safety concern
Checkpoint inhibitorInfusion, laboratory review, symptom check, and observationDelayed inflammation of an organ
Combination treatmentMore than one drug, with closer review of symptoms and test resultsHigher risk of treatment-related toxicity
CAR-T or other cellular therapyCell infusion in a specialist centre with prolonged monitoringCytokine-release syndrome or immune effector cell-associated neurotoxicity syndrome

Immune-related adverse events can appear weeks or months after treatment starts, and sometimes after treatment stops. Report new diarrhoea, blood in stool, severe abdominal pain, yellow skin, dark urine, reduced urination, chest pain, severe rash, or extreme fatigue promptly; colitis, hepatitis, nephritis, skin inflammation, and myocarditis can become life-threatening.

Pneumonitis may cause a new cough, chest discomfort, or shortness of breath.

  • Seek urgent help for fever, faintness, low blood pressure, breathing difficulty, confusion, severe headache, weakness, or seizures after cellular therapy.
  • Ask for same-day medical advice rather than assuming symptoms are infection or cancer progression.
  • Doctors may pause treatment, order organ-specific tests, and prescribe corticosteroids or other immunosuppressive treatment. Thyroid or adrenal damage may require lifelong hormone replacement.

How Immunotherapy Compares with Chemotherapy and Targeted Therapy

In immunotherapy versus chemotherapy, the decisive difference is who does the damage: immune treatment recruits or redirects immune cells, while chemotherapy directly injures rapidly dividing cells. Targeted therapy takes a third route by blocking a defined cancer-driving protein or pathway. It works only while the tumour depends on that target.

OptionMain actionMain limitation
ImmunotherapyRemoves immune restraints or directs immune cells toward cancerNeeds recognizable cancer signals and a usable immune pathway
ChemotherapyDirectly damages dividing cellsAlso injures healthy fast-growing cells, such as bone-marrow and intestinal cells
Targeted therapyBlocks a specific cancer protein or growth pathwayResistance can emerge when the target changes or the tumour bypasses it

CAR-T therapy is an immune approach that equips a patient’s T cells with a receptor designed to recognize a cancer marker. Its effects therefore depend on the presence of that marker and can include serious immune or blood-related complications.

Doctors choose combination treatment when different mechanisms could cover one another’s weaknesses. An immune drug can expose or attack surviving cells after another treatment reduces the tumour, while a pathway-blocking drug can weaken cancer’s growth signals. The trade-off is greater toxicity, more monitoring, and more opportunities for resistance or treatment interruption.

A combination is not automatically better; cancer type, biomarkers, prior treatment, organ function, and the patient’s ability to tolerate side effects determine whether its added benefit justifies the risk.

Frequently asked questions

  • How does the immune system recognize cancer cells?

    T cells inspect protein fragments displayed on cell surfaces. Unusual fragments created by cancer-causing mutations can mark a cell for destruction.

  • How do tumors hide from the immune system?

    Tumors can reduce antigen presentation, create an immunosuppressive environment, or activate checkpoint signals that switch T cells off.

  • What are the main types of cancer immunotherapy?

    Immunotherapy includes checkpoint inhibitors, monoclonal antibodies, cancer vaccines, adoptive cell therapies such as CAR T-cell therapy, and immune-system modulators.

  • Which patients and cancers may benefit from immunotherapy?

    Eligibility depends on cancer type, stage, previous treatment, overall health, and biomarkers such as PD-L1 expression, microsatellite instability, or mismatch-repair deficiency.

  • What happens during an immunotherapy treatment visit?

    The care team reviews symptoms, medicines, examination findings, and blood tests before administering treatment and monitoring you for reactions.

Nov 20th, 2026 11:30 AM